Global Antibody Partnering Deals Collection 2014-2020 - Access to 1,300+ Online Deal Records; Headline, Upfront, Milestone and Royalty Data

DUBLIN, July 10, 2020 /PRNewswire/ -- The "Global Antibody Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

• Antibodies
• Antibody-drug conjugates
• Monoclonal antibodies
• Murine mAb
• Chimeric mAb
• Humanized mAb
• Human aAb
• Polyclonal Antibodies

Global Antibody Partnering Terms and Agreements 2014 to 2020 includes:

• Trends in Antibody dealmaking in the biopharma industry since 2014
• Analysis of Antibody deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life Antibody deals
• Access to over 1,300 Antibody online deal records
• The leading Antibody deals by value since 2014
• Most active Antibody dealmakers since 2014
• The leading Antibody partnering resources

The initial chapters of this report provide an orientation of Antibody dealmaking and business activities.

• Chapter 1 provides an introduction to the report.
• Chapter 2 provides an overview of the trends in Antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
• Chapter 3 provides a review of the leading Antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
• Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
• Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2014, where a contract document is available in the public domain. The Chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
• Chapter 7 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2014. The Chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise Antibody rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

• 3SBio
• 4D Pharma
• A*STAR Agency for Science
• Technology and Research
• A*STAR Singapore Immunology Network
• Aarhus University Hospital
• Abbvie
• Abcam
• AbCellera
• AbCheck
• AbClon
• Abcuro
• Ab E Discovery
• Abeome
• Abilita Bio
• Ab Initio
• ABL Bio
• Ablexis
• Ablynx
• AbMed
• Abpro
• Abveris
• Abzena
• Acceleron Pharma
• Accord Healthcare
• Aceno Biotherapeutics
• Acerta Pharma
• Achaogen
• AC Immune
• Acticor Biotech
• Actinium Pharmaceuticals
• Adagene
• AdAlta
• Adaptimmune
• Adaptive Biotechnologies
• ADC Therapeutics
• Adimab
• Adlai Nortye
• Aduro BioTech
• Advanced Biological Laboratories
• Advanced BioScience Laboratories
• Advanced Proteome Therapeutics
• Advantagene
• Advaxis
• Aeglea BioTherapeutics
• Aevi Genomic Medicine
• AffaMed Therapeutics
• Affibody
• Affilogic
• Affimed Therapeutics
• Affinita Biotech
• AGC Biologics
• Agensys
• Agenus Bio
• Agilvax
• AgomAb Therapeutics
• AgonOx
• AIMM Therapeutics
• Aimmune Therapeutics
• Akeso Biopharma
• Albert Einstein College of Medicine
• Alder Biopharmaceuticals
• Alector
• Alexion Pharmaceuticals
• Allakos
• Allele Biotechnology and Pharmaceuticals
• Allergan
• Alligator Bioscience
• Allogene Therapeutics
• Almirall
• Alpha Cancer Technologies
• Alphamab
• Alteogen
• Alvogen
• Alvotech
• Alytas Therapeutics
• Amag Pharmaceuticals
• Ambrx
• American Foundation for AIDS Research (amfAR)
• Amgen
• Amneal Pharmaceuticals
• Amplyx Pharmaceuticals
• AnaptysBio
• AnGes MG
• Angiex
• Anthera Pharmaceuticals
• Anthos Therapeutics
• Antidote Therapeutics
• Antigen Express
• Antikor Biopharma
• Antitope
• Apceth
• Apeiron Biologics
• Aperion Biologics
• Apexigen
• Aptevo Therapeutics
• Aquila BioMedical
• Arcus Biosciences
• arGEN-X
• argenx
• Aridis Pharmaceuticals
• ARMO Biosciences
• Array Biopharma
• Arsanis Biosciences
• Arsia Therapeutics
• Ascenion
• Ascentage Pharma
• Ascletis
• Aslan Pharma
• Aspyrian Therapeutics
• Astellas Pharma
• Astex Pharmaceuticals
• AstraZeneca
• Atara Biotherapeutics
• aTen Therapeutics
• Athenex
• Atlab Pharma
• Atlangram
• Atlante Biotech
• Atreca
• Austrian Institute of Technology
• Avacta
• AvantGen
• AVEO Oncology
• Avid Bioservices
• Avidity Biosciences
• Avillion
• AxioMx
• Aytu BioScience
• Back-A-Line
• Basilea Pharmaceutica
• Batavia Biosciences
• Bausch & Lomb
• Bavarian Nordic
• Baxalta
• Baxter International
• Bayer
• Bayer Healthcare
• Baylor Institute for Immunology Research
• BB100
• BeiGene
• Benchwise
• BerGenBio
• Berkeley Lights
• Beth Israel Deaconess Medical Center
• Biametrics
• Bill and Melinda Gates Foundation
• Bio-Techne
• Bio-Thera Solutions
• BioArctic Neuroscience
• biOasis Technologies
• BioAtla
• Biocare Medical
• Bioceros
• BiocerOX Products
• bioCSL
• Biocytogen
• Biodesix
• BioDuro
• Biofactura
• Bio Farma
• Biogen
• BioGenes
• BioInvent
• BioLegend
• BiolineRX
• bioLytical Laboratories
• BioMarker Strategies
• Biomax Informatics
• Biomedical Advanced Research and Development Authority
• Biomedical Catalyst Fund (UK)
• Biomunex Pharmaceuticals
• BioNovion
• BioNTech
• Biooutsource
• BioRap Technologies
• Biosceptre International
• Biotem
• Biothera
• Biotheus
• BioTie Therapies
• BioVectra
• BioVendor
• Bioventix
• BioWa
• BioXcel
• BliNK Biomedical
• BliNK Therapeutics
• Bliss Biopharmaceutical
• Bluebird Bio
• Blue Sky Biotech
• Boehringer Ingelheim
• Bpifrance
• Brigham and Women's Hospital
• Brii Biosciences
• Bristol-Myers Squibb
• Broad Institute
• C-Bridge Capital
• C2N Diagnostics
• Caerus Discovery
• Caliber Biotherapeutics
• and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/hl55c5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets